PowerPoint 프레젠테이션 - Hanmi · 2017-04-27 · 18 LAPSInsulin Combo HM14220 Diabetes...

2

3

4

5

6

7

8

9

10

11

-7.3%

2.1%

-2.7%

-3.2%

1.0%

11.5%

5.7%

5.8%

12

0%

%) TTB

%) TTB

%) TTB

13

-21.1% 31.4%

0.9% 25.3%

-19.1% 107.8%

-1.9% 25.0%

-25.6% -28.0%

35.9% 39.5%

-18.8% 8.3%

-15.0% 0%

14

15

16

17

18

LAPSInsulin Combo HM14220

Diabetes

SANOFI

GMB Stem Cell Therapy HM21001

Glioblastoma

AJOU Univ LAPSTriple Agonist

HM15211

Obesity

LAPSGCG Analog HM15136

Congenital Hyperinsulinism

LAPSlDS HM15410

Mucopoysaccharidosis

FLT3 Inhibitor HM43239

AML

PD-1/HER-2 BH2950

Breast, Gastric cancer

B

PD-1/PD-L1 BH2941

Cancer

B LAPSGLP-2 Analog

HM15410

Short Bowel Syndrome

Pre-Clinical Phase 2 Phase 3 Phase 1

LAPSGLP/GCG HM12525A

Diabetes/Obesity

JANSSEN

LAPSInuslin HM12470

Diabetes

Pan-RAF Inhibitor HM95573

Solid tumor

GENENTECH

Oratecan™ Irinotecan+HM30181A

Solid tumor

ATHENEX

Src/Tubulin KX2-391

Solid tumor

ATHENEX

PD-1/EGFR BH2922

NSCLC, Colorectal cancer

B

LAPSExd4 Analog Efpeglenatide

Diabetes/Obesity

SANOFI

LAPShGH Efpegsomatropin

GH deficiency

Olita® * Olmutinib

NSCLC

ZAI LAB

Luminate®

Integrin inhibitor

DME

ALLEGRO

BTK Inhibitor HM71224

Autoimmune diseases

ELI LILLY

Pan-HER Inhibitor Poziotinib

Solid tumor

SPECTRUM/LUYE

Rolontis™ Eflapegrastim Neutropenia

SPECTRUM

Oraxol™** Paclitaxel+HM30181A

Breast cancer

ATHENEX

Diabetes/Obesity

Rare Diseases

Cancer

Autoimmune Diseases

Others

B Beijing Hanmi

19